Recent progress in cancer cell membrane-based nanoparticles for biomedical applications

• Qixiong Lin,
• Yueyou Peng,
• Yanyan Wen,
• Xiaoqiong Li,
• Donglian Du,
• Weibin Dai,
• Wei Tian and
• Yanfeng Meng

Beilstein J. Nanotechnol. 2023, 14, 262–279, doi:10.3762/bjnano.14.24

• therapeutic approaches rely on chemotherapy, and other treatment methods usually cannot to achieve therapeutic effects. Acute myeloid leukemia (AML) is the most common type of leukemia and is characterized by rapid progression and high mortality [65]. Moreover, AML shows a heightened risk of recurrence

Gelatin nanoparticles with tunable mechanical properties: effect of crosslinking time and loading

• Agnes-Valencia Weiss,
• Daniel Schorr,
• Julia K. Metz,
• Metin Yildirim,
• Saeed Ahmad Khan and
• Marc Schneider

Beilstein J. Nanotechnol. 2022, 13, 778–787, doi:10.3762/bjnano.13.68

• that the transfection efficiency of cationized gelatin nanoparticles to myeloid leukemia cells (K562) highly depends on the elasticity [16]. Furthermore, it could be shown that stiffer particles were taken up faster in the alveolar epithelial cancer cell line A549 compared to their soft counterparts

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• efficacy of the cancer treatment. This article will focus on novel design strategies for nanoscale drug delivery systems, based on the unique molecular signatures of myeloid leukemia and EGFR/CD44-positive solid tumors, and the impact of novel discoveries in molecular tumor profiles on future

• chemotherapeutic protocols. Keywords: CD44; EGFR; liquid tumors; molecular tumor targeting; myeloid leukemia; solid tumors; surface-engineered nanoparticles; Introduction The conventional chemotherapy regimens of both liquid (hematological) and solid tumors are challenged by their lack of targeting ability

• cascades downstream the growth factor receptor mutations, which were detected in a variety of solid tumors, in diverse acute myeloid leukemia (AML) cells, and in many other leukemic cells, highlighted their role as therapeutic targets and the importance of novel therapeutic approaches and treatment